This reclassification entailed dividing APS patients into two distinct groups: those who tested positive for a single antiphospholipid antibody (such as LA, aCL, or anti-β2GPI) and those exhibiting positivity for more than one laboratory criterion, regardless of the combination. Here, APOH is linked to autoimmune polyendocrinopathy.